127 related articles for article (PubMed ID: 22629600)
1. [The influence of compound aITEL1296 on telomerase activity and the growth of cancer cells].
Kovalenko NA; Zhdanov DD; Bibikova MV; Gotovtseva VIu
Biomed Khim; 2011; 57(5):501-10. PubMed ID: 22629600
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells.
Bashash D; Zareii M; Safaroghli-Azar A; Omrani MD; Ghaffari SH
Hematology; 2017 Jul; 22(6):330-340. PubMed ID: 28054503
[TBL] [Abstract][Full Text] [Related]
3. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532.
El-Daly H; Kull M; Zimmermann S; Pantic M; Waller CF; Martens UM
Blood; 2005 Feb; 105(4):1742-9. PubMed ID: 15507522
[TBL] [Abstract][Full Text] [Related]
4. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.
Shi Y; Sun L; Chen G; Zheng D; Li L; Wei W
Target Oncol; 2015 Dec; 10(4):565-73. PubMed ID: 25916999
[TBL] [Abstract][Full Text] [Related]
5. Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies.
Biray Avci C; Dogan F; Ozates Ay NP; Goker Bagca B; Abbaszadeh Z; Gunduz C
J Cell Biochem; 2018 Dec; 119(12):9817-9824. PubMed ID: 30145821
[TBL] [Abstract][Full Text] [Related]
6. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition.
Zhao YM; Zhou Q; Xu Y; Lai XY; Huang H
Acta Pharmacol Sin; 2008 Apr; 29(4):481-8. PubMed ID: 18358095
[TBL] [Abstract][Full Text] [Related]
8. Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line.
Pourbagheri-Sigaroodi A; Bashash D; Safaroghli-Azar A; Farshi-Paraasghari M; Momeny M; Mansoor FN; Ghaffari SH
Eur J Pharmacol; 2019 Mar; 846():49-62. PubMed ID: 30658112
[TBL] [Abstract][Full Text] [Related]
9. Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells.
Bashash D; Ghaffari SH; Mirzaee R; Alimoghaddam K; Ghavamzadeh A
Leuk Lymphoma; 2013 Mar; 54(3):561-8. PubMed ID: 22957790
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate.
Pascolo E; Wenz C; Lingner J; Hauel N; Priepke H; Kauffmann I; Garin-Chesa P; Rettig WJ; Damm K; Schnapp A
J Biol Chem; 2002 May; 277(18):15566-72. PubMed ID: 11854300
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells.
Khaw AK; Silasudjana M; Banerjee B; Suzuki M; Baskar R; Hande MP
Mutat Res; 2007 Dec; 625(1-2):134-44. PubMed ID: 17669439
[TBL] [Abstract][Full Text] [Related]
12. Telomerase inhibition regulates EMT mechanism in breast cancer stem cells.
Kusoglu A; Goker Bagca B; Ozates Ay NP; Gunduz C; Biray Avci C
Gene; 2020 Oct; 759():145001. PubMed ID: 32738420
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of telomerase recruitment and cancer cell death.
Nakashima M; Nandakumar J; Sullivan KD; Espinosa JM; Cech TR
J Biol Chem; 2013 Nov; 288(46):33171-80. PubMed ID: 24097987
[TBL] [Abstract][Full Text] [Related]
14. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and SARs of novel telomerase inhibitors based on BIBR1532.
Liu C; Zhou H; Sheng XB; Liu XH; Chen FH
Bioorg Chem; 2020 Sep; 102():104077. PubMed ID: 32682156
[TBL] [Abstract][Full Text] [Related]
16. Structural Basis of Telomerase Inhibition by the Highly Specific BIBR1532.
Bryan C; Rice C; Hoffman H; Harkisheimer M; Sweeney M; Skordalakes E
Structure; 2015 Oct; 23(10):1934-1942. PubMed ID: 26365799
[TBL] [Abstract][Full Text] [Related]
17. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
18. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines.
Parsch D; Brassat U; Brümmendorf TH; Fellenberg J
Cancer Invest; 2008 Jul; 26(6):590-6. PubMed ID: 18584350
[TBL] [Abstract][Full Text] [Related]
19. Screening of telomerase inhibitors.
Kleideiter E; Piotrowska K; Klotz U
Methods Mol Biol; 2007; 405():167-80. PubMed ID: 18369824
[TBL] [Abstract][Full Text] [Related]
20. Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.
Celeghin A; Giunco S; Freguja R; Zangrossi M; Nalio S; Dolcetti R; De Rossi A
Cell Death Dis; 2016 Dec; 7(12):e2562. PubMed ID: 28032863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]